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Skin rash (62.2%), asthenia (34.1%) and diarrhoea (30.1%) were the 
most frequent toxicities. 
Conclusions: This subgroup analysis conﬁrms the activity of Erlotinib 
in male patients with advanced NSCLC. Survival beneﬁt was also evi-
dent and no differences between subgroups were observed (with the ex-
ception of performance status). This retrospective analysis, along with 
the subgroup analyses of the BR.21 study, suggests that at this moment, 
gender should not be a criterion to decide treatment with Erlotinib.
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Background: Poor performance status is one of the prognostic factors 
in patient with lung cancer; this group constitutes between 30%-40% 
of the patients with advanced non small cell lung cancer (NSCLC) and 
has a low life expectancy. Erlotinib, an oral inhibitor of the Epidermal 
Grow Factor (EGFR) have demonstrated to improve survival, prolong 
disease progression, and delay worsening of cancer-related symptoms, 
with a mild safety proﬁle, which make Erlotinib an ideal candidate to 
treat those patients with poor performance status (PS). Here we present 
results of an analysis of a large subgroup of patients with PS =2 in a 
Phase II prospective study (TargeT), in order to determine the efﬁcacy 
and safety of Erlotinib in that population.
Methods: Patient with histologically conﬁrmed stage IIIB or IV 
NSCLC, that were ≥ 18 year old, had adequate bone marrow, he-
patic, and renal function, were pretreated with chemotherapy or were 
untreated patients that were not suitable for ﬁrst line conventional 
chemotherapy were included in the TargeT trial. Patients with poor 
performance status (ECOG = 2) were included in this sub analysis. 
Patients were treated with Erlotinib single agent 150 mg/day p.o. until 
disease progression or withdrawal. Evaluation of the safety proﬁle was 
determined by NCI CTCAE version 3.0.
Results: 386 patients with poor PS and advanced NSCLC were ana-
lyzed in this study. Median age was 67 years (range 28-95), 99% of the 
patients were Caucasian, there was 73.8% males and 26.2% females. 
The stage of the patients was: IIIB/ 18.9% and IV 81.9%. The Histol-
ogy was adenocarcinoma / squamous / large cell / others 54%, 22%, 
18% and 6% respectively. First line patients were 35%, 2nd line 34% 
and 3rd line 31%. Current smokers or patients that have smoked were 
78%. In the population evaluable for response (148 patients), 1 CR, 23 
PR, 57 SD were observed (ORR 16.2%). Clinical beneﬁt (CR+PR+SD) 
was 54.7%. RR is much higher in females (34.8%) than males (8.6%) 
(p<0.0001) and in never smokers (45.7%) than in smokers (7.2%) 
(p<0.0001). Median TTP was 3.33 months (95% CI 2.7 - 5.1). The mul-
tivariate analysis showed that no smoking history correlated with better 
TTP (p<0.0025).Rash was the predominant toxicity occurring in 44.8% 
of the patients and diarrhea was observed in 24%, but only one grade 4 
was reported. 
Conclusions: Erlotinib is safe, well tolerated and active in patients 
with advanced NSCLC and poor performance status. In the multivariate 
analysis, smoking history is the main predictive factor. Further studies 
in this population are warranted.
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Background: Erlotinib is a selective EGFR inhibitor approved for the 
treatments of patients with non-small cell lung cancer (NSCLC) after 
failure of at least one prior chemotherapy. Although third line treatment 
is not often an option for NSCLC due to the decline in the performance 
status and to the aggravation of symptoms, here we present results of 
an analysis of a large subgroup of patients treated in third or more lines 
in a Phase II prospective study (TargeT).
Methods: Patients with IIIB-IV stage, performance status ≤2, adequate 
bone marrow, hepatic and renal functions, that were previously treated 
for advanced or metastastic NSCLC were included in the TargeT study. 
Erlotinib was given at a dose of 150 mg/day until disease progression 
or withdrawal. Results from patients who received at least two previous 
regimen of treatment were analyzed. Evaluation of response rate (ac-
cording to RECIST criteria), time to progression (TTP), survival and 
safety proﬁle was performed.
Results: 503 patients treated in the TargeT study were on third or 
further line of treatment. Median age was 60 years (range 32-84), 99 
% of them were Caucasian. All of them had received two or more 
previous therapies for metastatic disease. 82% of the patients were 
male and 88% were current or former smokers. Performance status 
0/1/2 was 20%/56%/24% respectively. In 43% of the patients tumor 
histology was adenocarcinoma. 293 patients had measurable disease 
and were evaluable for response. 2 CR, 30 PR (ORR 10.9%), 111 SD 
and 150 PD were observed. Rate of clinical beneﬁt (CR+PR+SD) was 
48.8%. RR was much higher in never smokers (36.4%) than in current 
or former smokers (7.4%, p<0.0001) and in women (25%) than in men 
(7.6%, p<0.0002). 
Analyzing the population by intention to treat median time to progres-
sion (TTP) was 3.2 months (95% CI 2.8–C3.7) and median survival 
time 5.6 months (95% CI 4.6–C6.4). The multivariate analysis showed 
that never smoking history was signiﬁcantly correlated with a better 
TTP (p<0.0026) and overall survival (OS) (p<0.0028).
Erlotinib was well tolerated and no unexpected toxicities were ob-
served. Rash and diarrhea were the most frequent adverse events.
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Conclusions: This subgroup analysis conﬁrms that erlotinib is an ac-
tive and safe therapy when used as third or successive line of treatment 
in patients with advanced or metastatic disease. In the multivariate 
analysis never smoking history is the most signiﬁcant predictive factor 
for longer TTP and OS.
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Background: Erlotinib, an oral HER-1/EGFR TKI is approved for 
patients with locally advanced or metastatic NSCLC after failure of 
at least one prior chemotherapy regimen. Erlotinib showed beneﬁt in 
terms of response rate, time to progression, and overall survival in a 
randomized, placebo-controlled trial. Although exploratory analysis 
demonstrated that the clinical beneﬁt of erlotinib was observed across 
most patient subgroups, this beneﬁt seemed to be greater in certain 
patients groups. Some authors have recommended considering salvage 
chemotherapy in the 2nd line setting instead of erlotinib for those 
patients with a good performance status. The purpose of the analysis 
we present here is to describe clinical outcome in the group of patients 
with NSCLC who presented with good PS (0–1)
Methods: The TargeT trial was an open-label, multicenter, non-ran-
domized phase II clinical trial carried out in 103 Spanish institutions. 
Patients with histologically conﬁrmed stage IIIB or IV NSCLC who 
had received treatment with chemotherapy in second or third line as 
well as chemotherapy-naïve patients non suitable for ﬁrst line conven-
tional chemotherapy were eligible. Eligibility criteria were: ≥18 years 
old, ECOG 0–2, adequate bone marrow, hepatic and renal function and 
written informed consent. Male patients receiving erlotinib 150 mg/day 
p.o until disease progression or withdrawal were the subject of this 
analysis. 
Results: From April 2004 to March 2006, 1,796 patients were included 
in the TargeT trial, of those 1,153 (64%) presented with performance 
status ECOG 0–1 at the beginning of the treatment with erlotinib, be-
ing the subject of this analysis. Main baseline characteristics: median 
age 64 years (range 26-89); 71% were male and 78% active or former 
smokers; histology: 53% adenocarcinoma (including BAC), 26% squa-
mous; 15% large cell carcinoma; 7% other; 82% had metastatic disease. 
Percentage of patients receiving erlotinib in 1st/2nd/3rd or further lines 
was: 27/40/33.
Among 731 patients with evaluable disease, treatment with erlotinib 
yielded an overall response rate (RR) of 19% and 39% of stabiliza-
tion of disease, for an overall control disease rate of 58%. Higher RRs 
were associated with female gender (36%; p<0.0001), non-smoking 
history (41%; p<0.0001), adenocarcinoma histology (26%; p<0.0001) 
and treatment with erlotinib in the ﬁrst line setting (33%; p<0.0001), in 
the univariate analysis. Similar associations were detected in terms of 
disease control ratio (60–70% in all subsets).
In the ITT population, median TTP was 4.1 months [95% CI 3.6–4.5] 
and median overall survival was 7.2 months (95% CI 6.5–7.8). Treat-
ment with erlotinib in chemo-naïve patients and the absence of smok-
ing habits were predictive factors for both a longer TTP and overall 
survival in the multivariate analysis. It deserves a mention that the 
subgroup of patients treated with erlotinib in the ﬁrst line setting (59% 
men; 76% stage IV; 63% non-smokers) reached a median OS of 9.4 
months (95% CI: 7.6–12.0), whilst non-smokers (79% treated in 2nd, 
3rd or further lines) showed a median OS of 13.4 months (95% CI: 
10.0–16.7).
Treatment with erlotinib was well tolerated and non unexpected toxici-
ties were reported. Skin rash and diarrhoea were the most common 
reported toxicities.
Conclusions: Erlotinib is active and well tolerated in patients with 
good performance status. Indirect comparisons suggest meaningful 
beneﬁt of erlotinib in patients with PS ECOG 0–1. On the basis of 
these results, there is no rational to delay the treatment with erlotinib in 
patients with good performance status, therefore potential candidates to 
receive conventional chemotherapy.
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Background: Erlotinib, an EGFR tyrosine kinase inhibitor, is a new 
second-line therapeutic option for patients with NSCLC. Erlotinib has 
been shown to achieve comparable improvement in overall survival, 
but with a more favourable side effect proﬁle than standard chemo-
therapy regimens. Another advantage of this agent is the use of oral 
administration. The favourable tolerability proﬁle of erlotinib may be 
beneﬁcial to the patients’ quality of life, and may lead to cost-savings 
for the health care system. The objective of this study was to evaluate 
the costs of treatment per patient in Germany for erlotinib, docetaxel 
and pemetrexed, taking into account the costs of managing adverse 
events (AEs).
Methods: The treatment regimens considered were continuous 
daily dosing with erlotinib (150mg/day, p.o.), and a 21-day cycle of 
docetaxel (75mg/m2 i.v.) or pemetrexed (500mg/m2 i.v.). Base costs 
and total costs per patient per quarter were calculated for the three 
regimens. The base costs comprised the outpatient costs for medical 
surveillance, drugs and drug administration, disregarding the costs of 
managing AEs. Costs of co-medications (dexamethasone for patients 
treated with docetaxel; dexamethasone, folic acid and vitamin B12 for 
patients treated with pemetrexed) were also considered. Total costs 
included the base costs plus, for each regimen, the average cost per 
patient of treating AEs in outpatient and inpatient facilities (only grade 
3/4 AEs (NCIC-CTC) were considered). Resource utilisation data were 
obtained from two multinational, randomized phase III trials in patients 
